Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

blonca9
Apr 23
1 min read

He describes the clinical data in FA cardiomyopathy that was announced this month, and explains how the company is preparing to begin a clinical trial for accelerated approval by early 2026. Plus, how we should expect more ACM data in 2025.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight